This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, H.-M. Articles by Thompson, T. C. Search for Related Content PubMed PubMed Citation Articles by Lee, H.-M. Articles by Thompson, T. C.

Resistance to Lysis by Cytotoxic T Cells: A Dominant Effect in Metastatic Mouse Prostate Cancer Cells¹

Scott Department of Urology [H-M. L., T. L. T., T. C. T.], Cell Biology [T. C. T.], and Radiology [T. C. T.], Baylor College of Medicine, and Veterans Affairs Medical Center (H-M. L., T. L. T., T. C. T.), Houston, Texas 77030

Better understanding of the immunology of prostate cancer is needed for the development of new therapeutic approaches that can be used in conjunction with current treatment methods. The present study was designed to compare the immunological properties of a genetically matched pair of primary tumor- and metastasis-derived prostate cancer cell lines generated from the mouse prostate reconstitution (MPR) model. Only the primary prostate cancer cells were immunogenic in that prior immunization with irradiated primary but not the metastatic prostate cancer cells delayed the growth of subsequently injected live cancer cells. The lack of immunogenicity of the metastatic cells was not attributable to their inability to induce antitumor cytotoxic T cells. Both primary and metastatic cells induced antitumor CTLs in syngeneic hosts, but unlike the primary cells, the metastatic cells were resistant to CTL lysis. Differential resistance to cytolysis in metastatic versus primary prostate cancer cells was not attributable to the differential expression of molecules such as transporter associated with antigen processing (TAP)-1, TAP-2, low molecular weight protein of the proteasome complex (LMP)-2, and LMP-7 that contribute to antigen presentation by class I MHC. IFN- induced surface class I MHC expression, as well as gene expression of TAP-1, TAP-2, LMP-2, and LMP-7 in the metastatic cells, yet the cells remained resistant to cell lysis induced by CTLs. Interestingly, although in comparison to the primary cells the metastatic cells were resistant to cytolysis, both cell types were susceptible to DNA fragmentation induced by CTLs. Cell fusion between primary and metastatic cancer cells resulted in hybrids that also resisted the cytolytic activity of CTLs. Therefore, there is a dominant factor(s) in the metastatic prostate cancer cells that confers specific protection against CTL cytolysis in this model system.

This article has been cited by other articles:

				A. F. Setiadi, M. D. David, R. P. Seipp, J. A. Hartikainen, R. Gopaul, and W. A. Jefferies Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas Mol. Cell. Biol., November 15, 2007; 27(22): 7886 - 7894. [Abstract] [Full Text] [PDF]

				A. F. Setiadi, M. D. David, S. S. Chen, J. Hiscott, and W. A. Jefferies Identification of Mechanisms Underlying Transporter Associated with Antigen Processing Deficiency in Metastatic Murine Carcinomas Cancer Res., August 15, 2005; 65(16): 7485 - 7492. [Abstract] [Full Text] [PDF]

				T. Satoh, T. Saika, S. Ebara, N. Kusaka, T. L. Timme, G. Yang, J. Wang, V. Mouraviev, G. Cao, E. M. A. Fattah, et al. Macrophages Transduced with an Adenoviral Vector Expressing Interleukin 12 Suppress Tumor Growth and Metastasis in a Preclinical Metastatic Prostate Cancer Model Cancer Res., November 15, 2003; 63(22): 7853 - 7860. [Abstract] [Full Text] [PDF]

				A. H. Shah, W. B. Tabayoyong, S. D. Kundu, S.-J. Kim, L. Van Parijs, V. C. Liu, E. Kwon, N. M. Greenberg, and C. Lee Suppression of Tumor Metastasis by Blockade of Transforming Growth Factor {beta} Signaling in Bone Marrow Cells through a Retroviral-mediated Gene Therapy in Mice Cancer Res., December 15, 2002; 62(24): 7135 - 7138. [Abstract] [Full Text] [PDF]

				C. K. Donawho, M. W. Pride, and M. L. Kripke Persistence of Immunogenic Pulmonary Metastases in the Presence of Protective Anti-melanoma Immunity Cancer Res., January 1, 2001; 61(1): 215 - 221. [Abstract] [Full Text]

				G. W. Hull, M. A. McCurdy, Y. Nasu, C. H. Bangma, G. Yang, S. Shimura, H.-M. Lee, J. Wang, J. Albani, S. Ebara, et al. Prostate Cancer Gene Therapy: Comparison of Adenovirus-mediated Expression of Interleukin 12 with Interleukin 12 plus B7-1 for in Situ Gene Therapy and Gene-modified, Cell-based Vaccines Clin. Cancer Res., October 1, 2000; 6(10): 4101 - 4109. [Abstract] [Full Text]